Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mdr Gutiérrez Cívicos"'
Autor:
AC Viney, Mdr Gutiérrez Cívicos, D Gutiérrez-Meca Maestre, I Muñoz García, P Conesa Zamora, A García Márquez, R Guerrero Bautista, MH García Lagunar, E Ferris Villanueva, I Español Morales
Publikováno v:
European Journal of Hospital Pharmacy. 23:A191.2-A191
Background Interindividual variability in treatment response may be associated with the presence of gene polymorphisms. Monoclonal antibodies seem to exert, at least partly, their mechanism of action by inducing apoptosis in antigen expressing cells.
Autor:
A García Márquez, E Ferris Villanueva, Mdr Gutiérrez Cívicos, D Lacruz Guzmán, M Martínez Penella, R Guerrero Bautista, I Muñoz García, MH García Lagunar, V Alice Charlotte, AM Chica Marchal
Publikováno v:
European Journal of Hospital Pharmacy. 23:A35.3-A36
Background Oncology patients are susceptible to malnutrition and this is a risk factor for morbidity and mortality. Purpose To evaluate nutritional status in patients treated with oral chemotherapy in a tertiary hospital. Material and methods Prelimi
Autor:
A García Márquez, E Ferris Villanueva, AC Viney, R Guerrero Bautista, Mdr Gutiérrez Cívicos, A De Béjar Almira, C Fuentes Gutiérrez, MH García Lagunar, AM Chica Marchal, I Muñoz García
Publikováno v:
European Journal of Hospital Pharmacy. 23:A38.1-A38
Background Palivizumab is a monoclonal antibody that provides passive immunity against respiratory syncytial virus (RSV) and has very specific criteria for use that have changed recently. According to the literature data, the annual incidence of bron
Autor:
R Guerrero Bautista, AM Chica Marchal, MH García Lagunar, García Simón, A García Márquez, I Muñoz García, M Martínez Penella, Mdr Gutiérrez Cívicos, E Ferris Villanueva, D Lacruz Guzmán
Publikováno v:
European Journal of Hospital Pharmacy. 22:A13.2-A14
Background The use of drugs during pregnancy is always controversial. There is limited information about the use of infliximab during pregnancy. Purpose To describe the effectiveness and safety of infliximab in a patient with ankylosing spondylitis d